Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Platinum-resistant Ovarian Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 610Carboplatin 376Paclitaxel 283Cisplatin 269Gemcitabine 256Pemetrexed 195Bevacizumab 191Nivolumab 190Docetaxel 190Injections 169Cyclophosphamide 148atezolizumab 138Capecitabine 134Fluorouracil 133Oxaliplatin 132Dexamethasone 129Fulvestrant 115durvalumab 114130-nm albumin-bound paclitaxel 111fludarabine 102Cetuximab 101Leucovorin 97Rituximab 96venetoclax 90Lenalidomide 84Prednisone 79enzalutamide 78Azacitidine 76Irinotecan 74Ipilimumab 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × afuresertib × 1 year × Clear all
NCT04851613 2026-04-02

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Laekna Limited

Phase 3 Active not recruiting
256 enrolled
Breast

Breast Neoplasms

NCT05383482 2025-11-17

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Laekna Limited

Phase 1/2 Completed
22 enrolled
GastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Endometrial Neoplasms

NCT04374630 2025-09-10

PROFECTA-II

Laekna Limited

Phase 2 Completed
150 enrolled
Gynecologic

Platinum-resistant Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡